Select Language
Free Registration

Complement C1s

Complement C1s Overview

English NameComplement C1sApproved Drugs4
Drugs in Clinical Trials5Target SynonymEC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Highest Development StageApproved
English NameComplement C1s
Target SynonymEC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Approved Drugs4
Drugs in Clinical Trials5
Highest Development StageApproved

Complement C1s Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (1)Cynomolgus (1)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
COS-H52H3
Human
HEK293
Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)
COS-C52H3
Cynomolgus
HEK293
Cynomolgus Complement C1s Protein, His Tag (MALS verified)
Total: 2
  • 1

Complement C1s Background

Complement C1s is a serine protease and a key component of the C1 complex in the classical complement pathway. One C1q molecule binds to a tetramer composed of two C1r and two C1s proteases to form the intact C1 complex. C1s circulates as a zymogen until activated by proteolytic cleavage from activated C1r. Its essential function is to cleave complement components C4 and C2, thereby initiating the formation of the C3 convertase (C4b2a). This step is critical for triggering downstream immune effector functions, including opsonization, inflammation, and membrane attack complex formation.

Complement C1s Synonyms

EDSPD2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Complement-C1 inhibitor protein (Octapharma)Phase 3 ClinicalOctapharmaAngioedemas, Hereditary
Details
RiliprubartBIVV-020; SAR-445088; TNT-020Phase 3 ClinicalTrue North TherapeuticsAnemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic
Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical)Phase 3 ClinicalBoya Bio-Pharmaceutical Group Co LtdAngioedemas, Hereditary
Details
ClaseprubartDNTH103; DNTH-103Phase 3 ClinicalDianthus Therapeutics IncAutoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
C1 esterase inhibitor (Chengdu Institute of Biological Products)Phase 1 ClinicalChengdu Institute Of Biological Products Co LtdAngioedemas, Hereditary
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Conestat alfarhC1-INHApprovedPharming Group NvRhucin, Esterasine, RuconestEUAngioedemas, HereditaryPharming Group Nv2010-10-28Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency
Details
SutimlimabBIVV-009; TNT-009ApprovedTrue North TherapeuticsENJAYMOUnited StatesAnemia, Hemolytic, AutoimmuneRecordati Rare Diseases Inc2022-02-04Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic
Details
Complement C1 inhibitor protein (Shire ViroPharma)C1 INH-nf; C1-INH; SHP-616ApprovedSanquin Plasma Products BvCinryze, CetorUnited StatesAngioedemas, Hereditarynull2008-10-10Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation
Details
C1 esterase inhibitor (Human, CSL Behring)BI-3.012; CSL-830; CSL-842; CE-1145ApprovedCsl Behring LlcBerinert, Haegarda, Berinert 2000JapanAngioedemas, HereditaryCsl Behring Llc1990-06-29Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland